Clinical Trial Update: (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial comparing quizartinib monotherapy to salvage chemotherapy in FLT3-ITD–positive AML has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: AML | Phase 3 | Status: COMPLETED | Results posted: 2020-01-27